280 related articles for article (PubMed ID: 31062115)
1. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
[TBL] [Abstract][Full Text] [Related]
4. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
Barret M; Antoun S; Dalban C; Malka D; Mansourbakht T; Zaanan A; Latko E; Taieb J
Nutr Cancer; 2014; 66(4):583-9. PubMed ID: 24707897
[TBL] [Abstract][Full Text] [Related]
6. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
[TBL] [Abstract][Full Text] [Related]
7. Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
Sugiyama K; Narita Y; Mitani S; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Ando M; Tajika M; Muro K
Anticancer Res; 2018 Oct; 38(10):5859-5866. PubMed ID: 30275211
[TBL] [Abstract][Full Text] [Related]
8. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
[TBL] [Abstract][Full Text] [Related]
11. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Stangl-Kremser J; Suarez-Ibarrola R; Andrea D; Korn SM; Pones M; Kramer G; Marhold M; Krainer M; Enikeev DV; Glybochko PV; Tamandl D; Shariat SF; Baltzer P
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):309-315. PubMed ID: 31745255
[TBL] [Abstract][Full Text] [Related]
12. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
13. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.
Maddalena C; Ponsiglione A; Camera L; Santarpia L; Pasanisi F; Bruzzese D; Panico C; Fiore G; Camardella S; Caramia T; Farinaro A; De Placido S; Carlomagno C
World J Clin Oncol; 2021 May; 12(5):355-366. PubMed ID: 34131567
[TBL] [Abstract][Full Text] [Related]
15. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
16. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia in Metastatic Colorectal Carcinoma.
Büchler T; Hornová J
Klin Onkol; 2019; 32(6):406-410. PubMed ID: 31842559
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
20. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
